8-K: Kronos Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Kronos Bio announced its first quarter 2024 financial results, highlighting a cash runway into the second half of 2026 and progress in its clinical programs.

Summary

• Kronos Bio reported its financial results for the first quarter of 2024, with a net loss of $30.0 million, or $0.50 per share.
• The company's cash, cash equivalents, and investments totaled $152.0 million as of March 31, 2024.
• Research and development expenses were $14.2 million for the quarter, including $1.2 million in non-cash stock-based compensation.
• General and administrative expenses were $7.5 million, including $2.2 million in non-cash stock-based compensation.
• The company incurred $6.6 million in impairment of long-lived assets expense and $6.2 million in restructuring expense, which included $4.4 million in non-cash stock-based compensation.
• Kronos Bio anticipates its current cash resources will fund operations into the second half of 2026.
• The company is progressing its clinical programs, with a study update on KB-0742-1001 to be presented at ASCO in June 2024.
• IND-enabling studies for KB-9558 are expected to be completed in 2024, with a first-in-human study anticipated in the first half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's strong cash position and progress in clinical programs, although the net loss and restructuring costs temper the overall outlook.

Positives

• The company has a strong cash position of $152.0 million, providing a runway into the second half of 2026.
• Clinical programs for KB-0742 and KB-9558 are progressing as planned.
• The company is actively presenting data at major scientific conferences, increasing visibility and awareness of its research.
• The collaboration with Genentech and internal discovery programs continue to advance.

Negatives

• The company reported a net loss of $30.0 million for the first quarter of 2024.
• The company incurred significant expenses related to impairment of long-lived assets and restructuring, totaling $12.8 million.
• Operating expenses were $34.5 million for the quarter.

Risks

• The company faces risks associated with changes to the assumptions underlying estimated expenses and savings.
• Changes in the macroeconomic environment or competitive landscape could impact the business.
• There are risks associated with completing necessary preclinical studies and receiving regulatory clearance for clinical trials.
• The company has limited experience in conducting clinical trials.
• Results of preclinical studies and early clinical trials may not be predictive of future results.
• The company may need additional capital in the future.

Future Outlook

Kronos Bio anticipates sufficient resources to fund its planned operations into the second half of 2026 and expects to complete IND-enabling studies for KB-9558 by the end of 2024, with a first-in-human study anticipated in the first half of 2025. The company also looks forward to sharing progress on its collaboration with Genentech and internal discovery programs later this year.

Management Comments

• We have continued to make good progress towards our goals.
• We are looking forward to sharing a clinical update on the KB-0742 data to date at ASCO in June.
• We expect to complete the IND-enabling studies for KB-9558 by the end of 2024 and expect to dose our first patients in the first half of 2025.

Industry Context

This announcement is consistent with the typical progress updates and financial reporting of a clinical-stage biotechnology company. The focus on clinical trial progress and cash runway is common in this sector, as is the presentation of data at scientific conferences. The company's focus on small molecule therapeutics targeting deregulated transcription aligns with current trends in oncology drug development.

Comparison to Industry Standards

• The cash runway into the second half of 2026 is a positive sign for a company of this stage, as many similar companies need to raise capital more frequently.
• The R&D expenses of $14.2 million are within the expected range for a company with multiple clinical programs, but the restructuring and impairment costs are higher than some peers.
• Companies like Relay Therapeutics and Revolution Medicines, which are also focused on small molecule therapeutics, have similar timelines for clinical trial progression, but their financial situations and specific programs differ.
• The presentation of data at AACR and ASCO is a standard practice for companies in this sector, and Kronos Bio's participation is in line with industry norms.

Stakeholder Impact

• Shareholders will be interested in the company's cash runway and clinical progress.
• Employees will be impacted by the restructuring efforts.
• Customers and suppliers will be interested in the company's long-term viability and product development pipeline.
• Creditors will be interested in the company's financial stability and ability to meet its obligations.

Next Steps

• Kronos Bio will present a study update on KB-0742-1001 at ASCO in June 2024.
• The company will open expansion cohorts for KB-0742 at a new dose schedule in Q3 2024.
• IND-enabling studies for KB-9558 are expected to be completed in 2024.
• The first-in-human study for KB-9558 is anticipated to commence in the first half of 2025.

Key Dates

Keywords

Kronos Bio, clinical trials, cancer therapeutics, KB-0742, KB-9558, CDK9 inhibitor, p300 inhibitor, financial results, biotechnology, oncology